VistaGen Therapeutics | 8-K: Current report
Apr 26 13:57 ET
VistaGen Therapeutics | DEF 14A: Definitive information statements
Apr 16 06:05 ET
VistaGen Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Apr 5 17:34 ET
VistaGen Therapeutics | 8-K: Current report
Apr 1 17:29 ET
VistaGen Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Feb 13 16:57 ET
VistaGen Therapeutics | 8-K: Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
Feb 13 16:35 ET
VistaGen Therapeutics | 8-K: Current report
Jan 9 00:00 ET
VistaGen Therapeutics | 8-K: Current report
Jan 3 00:00 ET
VistaGen Therapeutics | 8-K: Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
Nov 9, 2023 16:42 ET
VistaGen Therapeutics | 8-K/A: Current report (Amendment)
Nov 6, 2023 21:46 ET
VistaGen Therapeutics | 8-K: Current report
Nov 6, 2023 16:27 ET
VistaGen Therapeutics | 8-K: Current report
Oct 26, 2023 16:13 ET
VistaGen Therapeutics | 8-K: Current report
Oct 4, 2023 16:07 ET
VistaGen Therapeutics | 8-K: Current report
Oct 2, 2023 07:15 ET
VistaGen Therapeutics | 8-K: Current report
Sep 29, 2023 16:26 ET
VistaGen Therapeutics | 8-K: Current report
Sep 12, 2023 20:43 ET
VistaGen Therapeutics | 8-K: Current report
Sep 8, 2023 17:27 ET
VistaGen Therapeutics | 8-K: Current report
Aug 22, 2023 08:40 ET
VistaGen Therapeutics | 8-K: Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
Aug 10, 2023 16:49 ET
VistaGen Therapeutics | 8-K: Current report
Aug 7, 2023 08:35 ET
No Data
No Data